Follow the people · Insider
J. Anthony Ware
J. Anthony Ware files insider transactions with the SEC as a director of First Tracks Biotherapeutics (TRAX). We hold 1 disclosed purchase or sale filed since 24 August 2017, 1 of them in the last 90 days.
- Files forTRAX
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure4 September 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 20 April 2026 — 2 September 2026Director · First Tracks Biotherapeutics (TRAX)23 Form 4 lines · source: SEC Form 4
- Filed 22 August 2017 — 6 January 2026Director · Anaptysbio (ANAB)23 Form 4 lines · source: SEC Form 4
Everything they disclosed
46 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 39,265 shares of First Tracks BiotherapeuticsSEC Form 44 September 2026Common Stock · traded 2 September 2026 · filed 4 September 2026
- ▼ sold on the open market 39,265 shares of First Tracks BiotherapeuticsSEC Form 44 September 2026Common Stock · traded 2 September 2026 · filed 4 September 2026
- exercised options over 28,571 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 44 September 2026Stock Option (right to buy) · traded 2 September 2026 · filed 4 September 2026
- exercised options over 10,694 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 44 September 2026Stock Option (right to buy) · traded 2 September 2026 · filed 4 September 2026
- exercised options over 6,030 shares of First Tracks BiotherapeuticsSEC Form 417 June 2026Common Stock · traded 15 June 2026 · filed 17 June 2026
- exercised options over 6,030 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 417 June 2026Restricted Stock Unit · traded 15 June 2026 · filed 17 June 2026
- was granted 2,500 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 412 June 2026Restricted Stock Unit · traded 12 May 2026 · filed 12 June 2026
- was granted 7,000 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 412 June 2026Stock Option (right to buy) · traded 12 May 2026 · filed 12 June 2026
- was granted 15,000 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 414 May 2026Restricted Stock Unit · traded 12 May 2026 · filed 14 May 2026
- was granted 42,000 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 414 May 2026Stock Option (right to buy) · traded 12 May 2026 · filed 14 May 2026
- was granted 28,571 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 16,510 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 5,500 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 6,030 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Restricted Stock Unit · traded 20 April 2026 · filed 22 April 2026
- was granted 4,000 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Restricted Stock Unit · traded 20 April 2026 · filed 22 April 2026
- was granted 10,694 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 6,000 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 6,000 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 11,000 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 11,000 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 9,200 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 10,600 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 16,510 shares of First Tracks Biotherapeutics (a derivative holding)SEC Form 422 April 2026Stock Option (right to buy) · traded 20 April 2026 · filed 22 April 2026
- was granted 5,500 shares of Anaptysbio (a derivative holding)SEC Form 48 January 2026Stock Option (right to buy) · traded 6 January 2026 · filed 8 January 2026
- was granted 4,000 shares of Anaptysbio (a derivative holding)SEC Form 48 January 2026Restricted Stock Unit · traded 6 January 2026 · filed 8 January 2026
- was granted 5,500 shares of Anaptysbio (a derivative holding)SEC Form 48 January 2026Stock Option (right to buy) · traded 6 January 2026 · filed 8 January 2026
- was granted 4,000 shares of Anaptysbio (a derivative holding)SEC Form 48 January 2026Restricted Stock Unit · traded 6 January 2026 · filed 8 January 2026
- ▼ sold on the open market 3,900 shares of AnaptysbioSEC Form 423 December 2025Common Stock · traded 23 December 2025 · filed 23 December 2025
- exercised options over 6,030 shares of Anaptysbio (a derivative holding)SEC Form 417 June 2025Restricted Stock Unit · traded 15 June 2025 · filed 17 June 2025
- exercised options over 6,030 shares of AnaptysbioSEC Form 417 June 2025Common Stock · traded 15 June 2025 · filed 17 June 2025
- was granted 16,510 shares of Anaptysbio (a derivative holding)SEC Form 47 January 2025Stock Option (right to buy) · traded 7 January 2025 · filed 7 January 2025
- was granted 6,030 shares of Anaptysbio (a derivative holding)SEC Form 47 January 2025Restricted Stock Unit · traded 7 January 2025 · filed 7 January 2025
- exercised options over 3,900 shares of Anaptysbio (a derivative holding)SEC Form 418 June 2024Restricted Stock Unit · traded 15 June 2024 · filed 18 June 2024
- exercised options over 3,900 shares of AnaptysbioSEC Form 418 June 2024Common Stock · traded 15 June 2024 · filed 18 June 2024
- was granted 16,510 shares of Anaptysbio (a derivative holding)SEC Form 45 January 2024Stock Option (right to buy) · traded 3 January 2024 · filed 5 January 2024
- was granted 6,030 shares of Anaptysbio (a derivative holding)SEC Form 45 January 2024Restricted Stock Unit · traded 3 January 2024 · filed 5 January 2024
- was granted 10,600 shares of Anaptysbio (a derivative holding)SEC Form 410 January 2023Stock Option (right to buy) · traded 6 January 2023 · filed 10 January 2023
- was granted 3,900 shares of Anaptysbio (a derivative holding)SEC Form 410 January 2023Restricted Stock Unit · traded 6 January 2023 · filed 10 January 2023
- was granted 9,200 shares of Anaptysbio (a derivative holding)SEC Form 414 February 2022Stock Option (right to buy) · traded 10 February 2022 · filed 14 February 2022
- was granted 11,000 shares of Anaptysbio (a derivative holding)SEC Form 412 February 2021Stock Option (right to buy) · traded 10 February 2021 · filed 12 February 2021
- was granted 11,000 shares of Anaptysbio (a derivative holding)SEC Form 413 February 2020Director Stock Option (Right to Buy) · traded 12 February 2020 · filed 13 February 2020
- ▲ bought on the open market 3,600 shares of AnaptysbioSEC Form 46 February 2020Common Stock · traded 10 December 2019 · filed 6 February 2020
- was granted 6,000 shares of Anaptysbio (a derivative holding)SEC Form 411 February 2019Director Stock Option (Right to Buy) · traded 8 February 2019 · filed 11 February 2019
- was granted 6,000 shares of Anaptysbio (a derivative holding)SEC Form 46 February 2018Director Stock Option (right to buy) · traded 2 February 2018 · filed 6 February 2018
- was granted 28,571 shares of Anaptysbio (a derivative holding)SEC Form 424 August 2017Director Stock Option (right to buy) · traded 22 August 2017 · filed 24 August 2017
- was granted 10,694 shares of Anaptysbio (a derivative holding)SEC Form 424 August 2017Director Stock Option (right to buy) · traded 22 August 2017 · filed 24 August 2017
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.